Relationship Between Acute Phase Reactants and Disability in Guillian-Barré Syndrome During the COVID-19 Pandemic
- 18 October 2021
- journal article
- research article
- Published by Elsevier BV in Archives of Medical Research
- Vol. 53 (2), 179-185
- https://doi.org/10.1016/j.arcmed.2021.10.002
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control studyThe Lancet, 2016
- Are Th17 cells and their cytokines a therapeutic target in Guillain–Barré syndrome?Emerging Therapeutic Targets, 2015
- Intravenous immunoglobulin for Guillain-Barré syndromeEmergencias, 2014
- Intravenous immunoglobulin for Guillain-Barré syndromePublished by Wiley ,2012
- Th17 cells in human diseaseImmunological Reviews, 2008
- A clinical prognostic scoring system for Guillain-Barré syndromeThe Lancet Neurology, 2007
- Guillain-Barré Syndrome and Preceding Infection with Campylobacter, Influenza and Epstein-Barr Virus in the General Practice Research DatabasePLOS ONE, 2007
- Absence of Diurnal Variation of C-Reactive Protein Concentrations in Healthy Human SubjectsClinical Chemistry, 2001
- Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: A practical, simple and clinically relevant approach in a large cohortJournal of Clinical Laboratory Analysis, 1999
- Assessment of current diagnostic criteria for Guillain-Barr syndromeAnnals of Neurology, 1990